Search Results for "hATTR"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
Vutrisiran: Dyspnea
Standard response letter on vutrisiran and the adverse event of dyspnea.
Standard response letter on vutrisiran and the adverse event of dyspnea.
Efficacy and Safety of Vutrisiran and Patisiran
Standard response letter on the efficacy and safety of vutrisiran and patisiran, summarizing data from the HELIOS-A study and the APOLLO study.
Standard response letter on the efficacy and safety of vutrisiran and patisiran, summarizing data from the HELIOS-A study and the APOLLO study.
Patisiran: Use in Patients with Renal Impairment
Standard response letter on patisiran and use in patients with renal impairment. The letter contains information from a post-hoc analysis in patients with ATTR and CKD across the APOLLO, APOLLO-B, Phase 3b Post-OLT, Phase 2 OLE, and Global OLE studies, as well as relevant information from a global safety database.
Standard response letter on patisiran and use in patients with renal impairment. The letter contains information from a post-hoc analysis in patients with ATTR and CKD across the APOLLO, APOLLO-B, Phase 3b Post-OLT, Phase 2 OLE, and Global OLE studies, as well as relevant information from a global safety database.
Patisiran: Cardiac Results from the APOLLO Study
Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
Standard response letter on patisiran and the exploratory cardiac results in the APOLLO study, a study evaluating the efficacy and safety of patisiran in patients with the polyneuropathy of hATTR.
